Richmond Pharmacology is excited to join the JSCTR Annual Meeting 2026 in Kobe, Japan, on 19–21 February 2026.

Bringing together leaders in clinical research, regulatory science, and trial operations, JSCTR serves as a key platform for advancing high‑quality clinical trials, promoting innovation in study design, and strengthening global collaboration across the clinical research community.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer
  • Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
  • Minoru Takada, Japanese Business Development Executive

Our Focus at the Conference

  • Innovations in clinical trial methodology
  • Regulatory harmonisation and emerging guidance
  • Best practices in global trial operations
  • Patient‑centric strategies in clinical development
  • Collaboration between academia, industry, and regulatory stakeholders

Connect With Us

If you are attending JSCTR 2026 and would like to explore partnership or development opportunities:

📧 japanbd@richmondpharmacology.com

Learn more here: Japanese Society of Clinical Trials (JSCTR)

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event